Company Executives

Management Team

From the proxy statement filed Sep 28, 2026

Officer	Age	In this role	Joined	2026 pay
Jacob P. Lalezari Chief Executive Officer	67	Since 2024 2 years	Not stated	$1,833,398
Robert E. Hoffman Chief Executive Officer Title from the Form 4 dated Oct 20, 2026	60	Not stated	Not stated	$1,899,609
Tyler Blok Chief Legal Officer and Corporate Secretary	39	Not stated	2022	$1,391,299

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Sep 28, 2026

Directors

serving now

Independent

5 of 5

stated in the proxy

Average tenure

Not stated

from year joined

CEO also chairs the board

Tanya D. Urbach

Director	Age	On board	Independent	Committees	Other public boards	2026 pay
Tanya D. Urbach Board chair	59	Not stated	Independent	Audit Committee Nominating and Corporate Governance Committee · Chair	None stated	$227,880
Lishomwa C. Ndhlovu, M.D., Ph.D.	56	Not stated	Independent	Nominating and Corporate Governance Committee	None stated	$174,382
Karen J. Brunke, Ph.D.	74	Not stated	Independent	Compensation Committee	None stated	$176,882
Ryan M. Dunlap	56	Not stated	Independent	Audit Committee · Chair	None stated	$194,382
Stephen M. Simes	74	Not stated	Independent	Compensation Committee · Chair	None stated	$194,382

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Sep 28, 2026

Dr. Lalezari

Current CEO of the Company; owns Lalezari Medical Corp., dba Quest Clinical Research

Approximately $0.2 million

Since June 1, 2024

Clinical Trial Agreements with Quest for clinical trial services; since June 1, 2024 the Company paid Quest for clinical trial services for leronlimab, with the largest total balance owed to Quest about $0.4 million and the outstanding balance about $0.2 million as of August 31, 2026.

With Lalezari Medical Corp., dba Quest Clinical Research (Quest) Open in proxy

Dr. Lalezari

Current CEO of the Company; owns Lalezari Medical Corp., dba Quest Clinical Research

Approximately $58,135

Since November 2023

Services performed at Quest, conducted by an independent contractor serving as designated principal investigator, incurred by the Company since Dr. Lalezari became CEO.

With Quest Open in proxy

Comments

Company Executives

Management Team

Board of Directors

Related-party transactions